Our data demonstrate that tissue specialization of IL-25-responsive tumor-promoting intestinal ILC2s have opposite functions to the tissue-specific IL-33-activated ILC2s that are protective in orthotopic pancreatic cancer and melanoma (15, 47). This evidence concerns the gene IL25 and familial pancreatic carcinoma.